tradingkey.logo
tradingkey.logo
検索

Immunome Inc

IMNM
ウォッチリストに追加
18.770USD
+0.070+0.37%
終値 11-13 16:00(ET)
2.21B時価総額
損失額直近12ヶ月PER

Immunome Incについて 企業名

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Immunome Inc プロフィール

企業コードIMNM
会社名Immunome Inc
上場日Oct 02, 2020
最高経営責任者「CEO」Siegall (Clay B)
従業員数118
証券種類Ordinary Share
決算期末Oct 02
本社所在地18702 N. Creek Parkway
都市BOTHELL
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号98011
電話番号16103213700
ウェブサイトhttps://immunome.com/
企業コードIMNM
上場日Oct 02, 2020
最高経営責任者「CEO」Siegall (Clay B)

Immunome Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
101.29K
+46.65%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
81.16K
-13.61%
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
69.81K
+77.36%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
56.25K
-7.11%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
43.41K
--
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
101.29K
+46.65%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
81.16K
-13.61%
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
69.81K
+77.36%

よくある質問

Immunome Incの上位5名の株主は誰ですか?

Immunome Incの上位5名の株主は以下のとおりです。Dr. Clay B. Siegall, Ph.D.

Immunome Inc(IMNM)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Immunome Incの株式を保有している機関は380社あり、保有株式の総市場価値は約116.25Mで、全体の102.66%を占めています。2025Q4と比較して、機関の持ち株は15805031.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。